CNDO Share Price

Open 3.97 Change Price %
High 4.03 1 Day -0.53 -13.35
Low 3.40 1 Week 0.00 0.00
Close 3.44 1 Month 0.00 0.00
Volume 893290 1 Year 0.00 0.00
52 Week High 63.25
52 Week Low 38.60
CNDO Important Levels
Resistance 2 4.02
Resistance 1 3.78
Pivot 3.62
Support 1 3.10
Support 2 2.86
NASDAQ USA Most Active Stocks
NVDA 100.49 -9.27%
JBHT 97.31 -1.05%
AREX 2.96 -1.99%
OZRK 55.54 1.02%
FNSR 34.15 0.12%
AGNC 19.64 0.72%
EA 86.65 -0.84%
FNFG 10.18 -0.20%
PRFZ 118.04 -0.80%
DELL 13.86 0.22%
More..
NASDAQ USA Top Gainers Stocks
ECTE 0.18 50.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
ZAZA 0.06 20.00%
JAKK 5.70 12.87%
LINE 0.18 12.50%
More..
NASDAQ USA Top Losers Stocks
DEER 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
EDMC 0.01 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Coronado Biosciences, Inc. (NASDAQ: CNDO)

CNDO Technical Analysis 3
As on 27th Apr 2015 CNDO Share Price closed @ 3.44 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.25 & Buy for SHORT-TERM with Stoploss of 3.32 we also expect STOCK to react on Following IMPORTANT LEVELS.
CNDO Target for February
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
CNDO Other Details
Segment EQ
Market Capital 124316320.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.coronadobiosciences.com
CNDO Address
CNDO
24 New England Executive Park
Suite 105
Burlington, MA 01803
United States
Phone: 781-652-4500
Fax: 781-652-4545
Interactive Technical Analysis Chart Coronado Biosciences, Inc. ( CNDO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Coronado Biosciences, Inc.
CNDO Business Profile
Coronado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. The Company�s two principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201 (TSO) a biologic comprising of the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohn�s disease (Crohn�s), ulcerative colitis (UC) and multiple sclerosis (MS), and CNDO-109, a compound that activates natural killer (NK) cells of the immune system to seek and destroy cancer cells, for the treatment of acute myeloid leukemia (AML). In January 2011, the Company acquired the OvaMed GmbH License.